Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Outcome of weekly carboplatin-paclitaxel-based definitive chemoradiation in oesophageal cancer in patients not considered to be suitable for platinum-fluoropyrimidine-based treatment: a multicentre, retrospective review

Owens, R., Cox, C., Gomberg, S., Pan, S., Radhakrishna, G., Parikh, S., Goody, R., Hingorani, M., Prince, S., Bird, T., Dorey, N., Macgregor, U., Al-Chamali, H., Hurt, C. ORCID: https://orcid.org/0000-0003-1206-8355 and Mukherjee, S. 2020. Outcome of weekly carboplatin-paclitaxel-based definitive chemoradiation in oesophageal cancer in patients not considered to be suitable for platinum-fluoropyrimidine-based treatment: a multicentre, retrospective review. Clinical Oncology 32 (2) , pp. 121-130. 10.1016/j.clon.2019.09.058

[thumbnail of CarboTaxol _Manuscript_RO (2) CH (1)SM(1)9793.pdf]
Preview
PDF - Accepted Post-Print Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (640kB) | Preview

Abstract

Aims Although cisplatin–fluoropyrimidine-based definitive chemoradiotherapy (dCRT) is a standard of care for oesophageal cancer, toxicity is significant and limits its use in elderly and frail patients. Weekly carboplatin–paclitaxel-based dCRT provides a viable alternative, although prospective data are lacking in the dCRT setting. Here we report the results of a national, multicentre retrospective review of outcome in patients treated with weekly carboplatin–paclitaxel-based dCRT. Materials and methods In this multicentre retrospective study of nine radiotherapy centres across the UK we evaluated the outcome of patients who had non-metastatic, histologically confirmed carcinoma of the oesophagus (adenocarcinoma, squamous cell or undifferentiated; World Health Organization performance status 0–2; stage I–III disease) and had been selected to receive weekly carboplatin–paclitaxel-based dCRT as they were considered not suitable for cisplatin–fluoropyrimidine-based dCRT. dCRT consisted of carboplatin AUC 2 and paclitaxel 50 mg/m2 (days 1, 8, 15, 22, 29) and the recommended radiation dose was 50 Gy in 25 daily fractions. We assessed overall survival, progression-free survival (PFS; overall, local and distant), proportion of patients who were failure free at the response assessment (12 weeks after dCRT), treatment compliance and toxicity. Results In total, 214 patients from nine UK centres were treated between 15 February 2013 and 19 March 2019: 39.7% of patients were ≥75 years; 18.7% ≥ 80 years. Indications for weekly carboplatin–paclitaxel-based dCRT were comorbidities (47.2%), clinician choice (36.4%) and poor tolerance/progression on cisplatin–fluoropyrimidine induction chemotherapy (15.8%). The median overall survival was 24.28 months (95% confidence interval 20.07–30.09) and the median PFS was 16.33 months (95% confidence interval 14.29–20.96). Following treatment, 69.1% (96/139) had a combined complete response on endoscopy with non-progression (complete response/partial response/stable disease) on imaging. The 1- and 2-year overall survival rates for this patient group were 81.9% (95% confidence interval 75.6–86.8%) and 50.6% (95% confidence interval 40.5–60.0%), respectively. Thirty-three per cent (n = 70) of patients experienced at least one grade 3 + acute toxicity (grade 3/4 haematological: 10%; grade 3/4 non-haematological: 32%) and there were no treatment-related deaths. 86.9% of patients completed at least four cycles of concomitant weekly carboplatin–paclitaxel-based chemotherapy and planned radiotherapy was completed in 97.7% (209/214). Conclusion Weekly carboplatin–paclitaxel-based CRT seems to be well tolerated in elderly patients and in those with comorbidities, where cisplatin–fluoropyrimidine-based dCRT is contraindicated. Survival outcomes are comparable with cisplatin–fluoropyrimidine-based dCRT.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Centre for Trials Research (CNTRR)
Publisher: Elsevier
ISSN: 0936-6555
Funders: CRUK
Date of First Compliant Deposit: 12 December 2019
Date of Acceptance: 11 September 2019
Last Modified: 06 Nov 2023 23:11
URI: https://orca.cardiff.ac.uk/id/eprint/127410

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics